Ticker: NTRB

Nutriband Inc. (NASDAQ: NTRB) Quick summary: Nutriband is growing product sales at its Pocono Pharmaceuticals unit and advancing its AVERSA abuse‑deterrent transdermal program with CDMO partner Kindeva. The company improved cash and working capital in H1 2025 but remains unprofitable and has sign...

Nutriband Inc. (NASDAQ: NTRB) has recently released its quarterly financial results for the period ending April 30, 2025. The company focuses on developing transdermal pharmaceutical products. Key Financial Highlights: Revenue: $667,432, up from $408,532 in the same period last year. Cost of Rev...